
On Monday, 27 states and the District of Columbia filed a lawsuit against 23andMe, aiming to block the company from selling customers' personal DNA information without their consent.
A bankruptcy court case is underway as Regeneron Pharmaceuticals moves forward with plans to purchase the struggling company for $256 million, ABC News said.